| abstract |
(57) [Summary]nThe present invention relates to therapeutic agents that antagonize the activity of glucagon. According to the present invention, the compound of the present invention comprises A glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or a sequence derived therefrom by phage display, RNA-peptide screening or other techniques; Includes a polymer (eg, PEG or dextran) or a vehicle such as an Fc domain, with an Fc domain being preferred. In this case, the vehicle is covalently linked to the glucagon antagonist domain. The vehicle and glucagon antagonist domain can be linked via the N-terminus or C-terminus of the glucagon antagonist domain. A preferred vehicle is an Fc domain, and a preferred Fc domain is an IgG Fc domain. |